Literature DB >> 18548130

Enantioselective Synthesis of Cyclopentyltetrahydrofuran (Cp-THF), an Important High-Affinity P2-Ligand for HIV-1 Protease Inhibitors.

Arun K Ghosh1, Jun Takayama.   

Abstract

A convenient optically active synthesis of (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[b]furan, a high-affinity nonpeptidyl ligand for HIV protease inhibitor 2, is described. The synthesis utilizes commercially available (1R,5S)-(+)-2-oxabicyclo[3.3.0]oct-6-en-3-one as the starting material and oxymercuration or bromohydrin reaction as the key step. Enantiopure ligand was converted to protease inhibitor 2.

Entities:  

Year:  2008        PMID: 18548130      PMCID: PMC2424253          DOI: 10.1016/j.tetlet.2008.03.116

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  8 in total

1.  AIDS--the first 20 years.

Authors:  K A Sepkowitz
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

Review 2.  Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Nagaswamy Kumaragurubaran; Yasuhiro Koh; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

3.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

4.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

5.  Chiral-catalyst-based convergent synthesis of HIV protease inhibitor GRL-06579A.

Authors:  Hisashi Mihara; Yoshihiro Sohtome; Shigeki Matsunaga; Masakatsu Shibasaki
Journal:  Chem Asian J       Date:  2008-02-01

Review 6.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

Authors:  Arun K Ghosh; Bruno D Chapsal; Irene T Weber; Hiroaki Mitsuya
Journal:  Acc Chem Res       Date:  2007-08-28       Impact factor: 22.384

7.  Public health implications of antiretroviral therapy and HIV drug resistance.

Authors:  M A Wainberg; G Friedland
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

Review 8.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

  8 in total
  3 in total

1.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

Review 2.  Organic carbamates in drug design and medicinal chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  J Med Chem       Date:  2015-01-07       Impact factor: 7.446

Review 3.  Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.

Authors:  Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  Viruses       Date:  2014-08-19       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.